Niagen Bioscience eyes double-digit growth. NASDAQ-listed NAGE targets 10-15% revenue expansion in 2026 while scaling its injectable product portfolio. The bioscience company outlined ambitious plans during its Q4 2025 earnings call, emphasizing margin improvements and strategic product diversification. Management highlighted the Niagen Plus injection kits as a key growth driver, alongside planned telehealth service expansion to reach broader customer segments. The company also addressed an ongoing FDA lawsuit, which investors are monitoring closely for potential impacts on operations and market positioning. Analysts suggest the growth targets reflect confidence in market demand and operational efficiency gains. NAGE shares reflect investor sentiment around these expansion initiatives and regulatory developments heading into 2026.